Abstracts tagged "patient engagement and psoriatic arthritis"

Abstract Number: 957 • 2016 ACR/ARHP Annual Meeting
International Patient and Physician Consensus on Psoriatic Arthritis Outcomes for Clinical Trials
Ana-Maria Orbai¹, Maarten de Wit², Philip J Mease³, Judy A. Shea⁴, Laure Gossec⁵, Ying Ying Leung⁶, William Tillett⁷, Musaab Elmamoun⁸, Kristina Callis Duffin⁹, Willemina Campbell¹⁰, Robin Christensen¹¹, Laura C. Coates¹², Emma Dures¹³, Lihi Eder¹⁴, Oliver FitzGerald¹⁵, Dafna D. Gladman¹⁶, Niti Goel¹⁷, Suzanne Grieb¹⁸, Sarah Hewlett¹⁹, Pil Hoejgaard²⁰, Umut Kalyoncu^21,22, Christine Lindsay²³, Neil J. McHugh²⁴, Bev Shea²⁵, Ingrid Steinkoenig²⁶, Vibeke Strand²⁷ and Alexis Ogdie²⁸, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Rheumatology, Paris 06 University, Paris, France, ⁶North District Hospital, Hong Kong, China, ⁷Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁹Department of Dermatology, University of Utah, Salt Lake City, UT, ¹⁰Toronto Western Hospital, Toronto, ON, Canada, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ¹²University of Leeds, Leeds, United Kingdom, ¹³Academic Rheumatology, Bristol, University of the West of England, Bristol, Bristol, United Kingdom, ¹⁴Women's College Research Institute, University of Toronto, Toronto, ON, Canada, ¹⁵Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College, Dublin, Ireland, ¹⁶Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁷Quintiles; Duke University School of Medicine, Durham, NC, ¹⁸Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ¹⁹Academic Rheumatology, University of West of England, Bristol, United Kingdom, ²⁰The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark, Denmark, ²¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²³Medical Affairs, Amgen Inc, Thousand Oaks, CA, ²⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom, ²⁵University of Ottawa, Ottawa, ON, Canada, ²⁶Patient Research Partner,, Cleveland, OH, ²⁷School of Medicine, Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: A psoriatic arthritis (PsA) core domain set to be measured in randomized controlled trials (RCT) was developed by Group for Research and Assessment…
Abstract Number: 2732 • 2016 ACR/ARHP Annual Meeting
Meaningful Involvement of Patients in the Development of a Core Outcome Set for Psoriatic Arthritis
Maarten de Wit¹, Alexis Ogdie², Willemina Campbell³, Philip J Mease⁴, Niti Goel⁵, Laure Gossec⁶, Ying Ying Leung⁷, Christine Lindsay⁸, Penelope Palominos Jr.⁹, Ingrid Steinkoenig¹⁰, Suzanne Grieb¹¹ and Ana-Maria Orbai¹², ¹Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ²University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵Quintiles; Duke University School of Medicine, Durham, NC, ⁶Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ⁷North District Hospital, Hong Kong, China, ⁸Medical Affairs, Amgen Inc, Thousand Oaks, CA, ⁹Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ¹⁰Patient Research Partner, Cleveland, OH, ¹¹Psychology, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The Group for Research of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group recently obtained endorsement at the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].